Determination of Boron Dose for BNCT Using Fricke and EPR Dosimetry

  • L. Wielopolski
  • B. Ciesielski

Abstract

In Boron Neutron Capture Therapy (BNCT), the dominant dose delivered to the tumor is due to α- and 7 Li-charged particles resulting from neutron capture by 10B and is referred to as the boron dose. Boron dose is directly attributable to its concentration and also to the neutron energy spectrum because the neutron capture cress-section in boron has an 1/v dependence. The distribution of neutron energy at a given point is dictated by the incident neutron-energy distribution, the depth in tissue, and geometrical factors such as the beam’s size and patient’s dimensions. These factors can be accounted for using Monte Carlo simulations1. However, when using conventional dosimetry for BNCT, e.g., TLDs or ionization chambers, boron dose can only be estimated. Many of the issues on BNCT dosimetry were addressed in Ref. 2.

Keywords

Electron Paramagnetic Resonance Boric Acid Electron Paramagnetic Resonance Spectrum Neutron Capture Boron Neutron Capture Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Yanch J.C., Zhou X-L., and Brownell G.L., A Monte Carlo investigation of the dosimetric properties of monoenergetic neutron beams for neutron capture therapy. Radiat. Res. 126, 1–20 (1991).PubMedCrossRefGoogle Scholar
  2. 2.
    Zamenhof R.G., Solares G.R., and Harling O.K., Eds., Topics in Dosimetry & Treatment Planning for Neutron Capture Therapy. Advanced Medical Publishing, Madison, Wisconsin. (1994).Google Scholar
  3. 3.
    Svensson H., and Brahme A., Ferrous sulphate dosimetry for electrons: A re-evaluation. Acta Radiologica Oncology 18, 326–336 (1979).CrossRefGoogle Scholar
  4. 4.
    Lawson R.C., and Porter D., The response of the ferrous sulfate dosemeter to neutrons. Phys. Med. Biol., 20, 420–430 (1975).PubMedCrossRefGoogle Scholar
  5. 5.
    Fregene A.O., Calibration of the ferrous sulphate dosimeter by ionometric and calorimetric methods. Nature 19, 818–819 (1966).CrossRefGoogle Scholar
  6. 6.
    Egusa S., Ishigure K., Tagawa S., Tabata Y., and Oshima K., Absorbed dose measurements in a mixed field of fast neutrons and gamma rays by the Fricke and ceric sulfate dosimeters. Radiat. Phys. Chem. 11, 129–134 (1978)CrossRefGoogle Scholar
  7. 7.
    Ciesielski B., and Wielopolski L., Application of Fricke dosimetry for BNCT. Advances in Neutron Captre Therapy, Eds Soloway A.H., Barth R.F., and Carpenter D.E., Plenum Press, New York, p53–57, (1993).Google Scholar
  8. 8.
    Regulla D.F., and Deffner U., Dosimetry of ESR spectroscopy of alanine. Int. J. Appl. Radiat. Isot. 33, 1101–1114, (1982).CrossRefGoogle Scholar
  9. 9.
    Schraube H., Weitzenegger E., Wieser A., and Regulla D.F., Fast neutron Response of alanine probes. Int. J. Appl. Radiat. Isot. 40, 941–944 (1989).CrossRefGoogle Scholar
  10. 10.
    Wielopolski L., Maryanski M., Ciesielski B., Forman A., Reinstein L.E., and Meek A.G. Continous three dimensional dosimetry in tissue-equivalent phantoms using electron paramagnetic resonance in L-a alanine. Med. Phys. 14, 646–652 (1987).PubMedCrossRefGoogle Scholar
  11. 11.
    Ciesielski B., and Wielopolski L., The effects of dose and radiation quality on the shape and power saturation of the EPR signal in alanine. Radiat. Res. 140, 105–111 (1994)PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • L. Wielopolski
    • 1
  • B. Ciesielski
    • 2
  1. 1.Medical DepartmentBrookhaven National LaboratoryUptonUSA
  2. 2.Department of Physics and BiophysicsMedical AcademyGdanskPoland

Personalised recommendations